Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 550% % -30%
Debt-to-equity 28% % 26%
Return On Equity -57% % -10%
Return On Assets -45% % -5.1%
Operating Margin -832% % 33%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115,829,926 shares 14%
Common Stock, Shares, Outstanding 115,787,285 shares 14%
Entity Public Float $1,916,954,312 USD -46%
Common Stock, Value, Issued $12,000 USD 20%
Weighted Average Number of Shares Outstanding, Basic 110,188,000 shares 9.1%
Weighted Average Number of Shares Outstanding, Diluted 110,188,000 shares 9.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $57,528,000 USD 34%
Research and Development Expense $417,086,000 USD -9%
General and Administrative Expense $119,169,000 USD -2.6%
Costs and Expenses $536,255,000 USD -7.7%
Operating Income (Loss) $478,727,000 USD 11%
Net Income (Loss) Attributable to Parent $445,806,000 USD 15%
Earnings Per Share, Basic -4 USD/shares 22%
Earnings Per Share, Diluted -4 USD/shares 22%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $193,389,000 USD 60%
Marketable Securities, Current $317,655,000 USD -41%
Accounts Receivable, after Allowance for Credit Loss, Current $11,050,000 USD 25%
Assets, Current $581,941,000 USD -18%
Property, Plant and Equipment, Net $20,421,000 USD -29%
Operating Lease, Right-of-Use Asset $117,883,000 USD 17%
Assets $925,275,000 USD -21%
Accounts Payable, Current $13,260,000 USD 0.88%
Employee-related Liabilities, Current $16,830,000 USD -18%
Accrued Liabilities, Current $40,841,000 USD -20%
Contract with Customer, Liability, Current $12,247,000 USD -45%
Liabilities, Current $93,726,000 USD -11%
Contract with Customer, Liability, Noncurrent $12,539,000 USD -45%
Operating Lease, Liability, Noncurrent $70,588,000 USD -14%
Liabilities $176,853,000 USD -16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $990,000 USD -70%
Retained Earnings (Accumulated Deficit) $2,494,308,000 USD -22%
Stockholders' Equity Attributable to Parent $748,422,000 USD -22%
Liabilities and Equity $925,275,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $148,930,000 USD -23%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $94,328,000 USD 1499%
Common Stock, Shares Authorized 240,000,000 shares 0%
Common Stock, Shares, Issued 115,787,285 shares 14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $54,602,000 USD 0.3%
Deferred Tax Assets, Valuation Allowance $783,211,000 USD 27%
Deferred Tax Assets, Gross $844,519,000 USD 30%
Operating Lease, Liability $97,966,000 USD
Payments to Acquire Property, Plant, and Equipment $735,000 USD -71%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $448,113,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid $117,651,000 USD
Property, Plant and Equipment, Gross $77,072,000 USD 6.1%
Operating Lease, Liability, Current $27,378,000 USD 43%
Lessee, Operating Lease, Liability, to be Paid, Year Two $24,125,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $32,219,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $19,685,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $15,637,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $296,766,000 USD 15%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $12,666,000 USD
Depreciation, Depletion and Amortization $9,971,000 USD -7.7%
Deferred Tax Assets, Net of Valuation Allowance $61,308,000 USD 89%
Share-based Payment Arrangement, Expense $103,097,000 USD -31%